ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2800

Adenosine 2a Receptor Signals Act to Limit Autoimmune Arthritis By Inhibiting Pathogenic Germinal Center T Follicular Helper (GC-Tfh) Cells

Shirdi Schmiel and Daniel L. Mueller, Medicine/Rheumatic and Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors, arthritis and tolerance, B cells, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T092 ACR Abstract: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2797–2801)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: CD4 germinal center (GC)-T follicular helper (Tfh) cells are important in the pathogenesis of autoimmune arthritis. Previous studies have shown that adenosine 2a receptor (A2aR, Adora2a) signaling can divert CD4 T cells away from the GC-Tfh cell lineage during the primary response to foreign antigens. Therefore, we examined the effects of A2aR signaling on CD4 T cells during the recognition of a self-antigen using a mouse model of autoimmune arthritis.

Methods: Wild type and Adora2a-deficient KRN TCR-transgenic CD4 T cells specific for glucose-6-phosphate isomerase (GPI)/I-Ag7 self-peptide were transferred into immunodeficient Tcra–/– I-Ag7-expressing mice to induce arthritis, and then recipients were treated with either the selective A2aR agonist CGS-21680 (CGS) or PBS vehicle alone. Severity of disease, autoantibody titers, KRN T cell numbers and phenotype, and GPI-specific isotype class-switched plasmablasts were tracked.

Results: CGS treatment inhibited arthritis development and KRN Bcl6hi CXCR5hi GC-Tfh cell differentiation, blocked the appearance of high affinity GPI-specific and IgG1 isotype class-switched polyclonal plasmablasts, and led to a reduction in anti-GPI IgG1 titers. Additionally, therapeutic administration of CGS after the onset of arthritis blocked further disease progression in association with reduced KRN GC-Tfh cell numbers and anti-GPI IgG1 titers. The therapeutic effects of CGS treatment were lost when the Adora2a gene was deleted only from the KRN T cells.

Conclusion: Strong A2aR signaling diverts autoreactive CD4 T cell differentiation away from the GC-Tfh lineage, thus reducing help for the differentiation of dangerous autoreactive B cells that promote arthritis. Therefore, our data suggest that the A2aR and its downstream signaling pathways in CD4 T cells may be promising therapeutic targets to interfere with autoreactive GC-Tfh cell differentiation.


Disclosure: S. Schmiel, None; D. L. Mueller, None.

To cite this abstract in AMA style:

Schmiel S, Mueller DL. Adenosine 2a Receptor Signals Act to Limit Autoimmune Arthritis By Inhibiting Pathogenic Germinal Center T Follicular Helper (GC-Tfh) Cells [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/adenosine-2a-receptor-signals-act-to-limit-autoimmune-arthritis-by-inhibiting-pathogenic-germinal-center-t-follicular-helper-gc-tfh-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adenosine-2a-receptor-signals-act-to-limit-autoimmune-arthritis-by-inhibiting-pathogenic-germinal-center-t-follicular-helper-gc-tfh-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology